These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30252199)

  • 21. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
    Ikeda J; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics on Drug Safety Measures in Japan Stratified by System Organ Classes and Therapeutic Categories in Relation to the Approval Date.
    Hiramatsu A; Hanaoka H; Uyama Y
    Ther Innov Regul Sci; 2020 Nov; 54(6):1534-1540. PubMed ID: 32524501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Signal Detection of Imipenem Compared to Other Drugs from Korea Adverse Event Reporting System Database.
    Park K; Soukavong M; Kim J; Kwon KE; Jin XM; Lee J; Yang BR; Park BJ
    Yonsei Med J; 2017 May; 58(3):564-569. PubMed ID: 28332362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
    Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Adverse drug reactions reported to the Brazilian pharmacovigilance system from 2008 to 2013: descriptive study].
    Mota DM; Vigo Á; Kuchenbecker RS
    Cad Saude Publica; 2019 Aug; 35(8):e00148818. PubMed ID: 31460613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of exposure model misspecification on signal detection in prospective pharmacovigilance.
    van Gaalen RD; Abrahamowicz M; Buckeridge DL
    Pharmacoepidemiol Drug Saf; 2015 May; 24(5):456-67. PubMed ID: 25187155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmarket safety communications on drugs approved in Japan: A 25-year analysis.
    Tanaka Y; Tanaka M; Miyazawa H; Terashima R; Miyazawa M; Ikuma M; Tomita Y
    Clin Transl Sci; 2024 Apr; 17(4):e13803. PubMed ID: 38651283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
    Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
    Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using Data from the Canadian Post-marketing Spontaneous Pharmacovigilance System for Drug Safety Research: A Feasibility Study.
    Akinola S; da Silveira CG; Corbin S; Lavallée M; Thibault M; Gonella J; Gimenes FRE; Leclerc J
    Pharmaceut Med; 2020 Aug; 34(4):263-269. PubMed ID: 32671791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database.
    Hosohata K; Inada A; Oyama S; Niinomi I; Wakabayashi T; Iwanaga K
    Clin Drug Investig; 2019 Apr; 39(4):363-368. PubMed ID: 30689189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Acute Kidney Injury Associated With Anticancer Drugs Used in Gastric Cancer in the Japanese Adverse Drug Event Report Database.
    Uchida M; Kondo Y; Suzuki S; Hosohata K
    Ann Pharmacother; 2019 Dec; 53(12):1200-1206. PubMed ID: 31347378
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacovigilance and communicating safety information.
    Drug Ther Bull; 2012 Dec; 50(12):138-40. PubMed ID: 23241564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the black triangle scheme and its online educational campaign on the quantity and quality of adverse drug event reporting in Australia: a time series analysis.
    Li R; Curtis K; Zaidi STR; Van C; Castelino R
    Expert Opin Drug Saf; 2020 Jun; 19(6):747-753. PubMed ID: 32207361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Research on Insufficient Information for Pharmaceutical Products].
    Tomita T
    Yakugaku Zasshi; 2017; 137(12):1497-1504. PubMed ID: 29199258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does Industry-Conducted All-Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?
    Suzuki A; Sato H; Sasaki Y
    Clin Transl Sci; 2019 Sep; 12(5):505-512. PubMed ID: 31062933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.